{"title":"Oral and Maxillo-facial Fungal Infections in COVID-19 Patients - A Systematic Review.","authors":"Preeti Sharma, Sangeeta Malik, Vijay Wadhwan, Kush Sharma, Anindita Chauhan, Rishabh Sharma","doi":"10.4103/ijdr.ijdr_691_23","DOIUrl":null,"url":null,"abstract":"<p><p>The main objective of the current systematic review was to compile and evaluate the data on opportunistic maxillofacial mycotic infections in COVID-19 patients during the treatment and post-recovery period of SARS-CoV-2 infection. Comorbidities like diabetes, corticosteroid use, and mortality among COVID-19-associated patients presenting with oral and maxillofacial fungal infections were also assessed. The review was conducted in accordance with Preferred Reporting Items for Systematic Review and Meta-analysis guidelines. A comprehensive search was carried out in the archives of Web of Science, Pubmed/Medline, Scopus, Google Scholar, Lilacs, and Livivo in combination with Boolean operators till 24th June 2022, and cross-sectional studies, case series, and case reports deliberating on maxillofacial mycoses in COVID-19 were included. The included studies were meted to the risk of bias using the Joana Briggs Institute Appraisal tools for prevalence studies, case series, and case reports. In a two-stage collection, 20 studies were included: 9 observational (3269 patients), 5 case-series (42 patients), and 6 case reports (8 patients) from 7 countries. Mucormycosis was the most commonly reported maxillofacial fungal infection (96.7%/3162 cases), followed by candidiasis (3.2%/105 cases) associated with COVID-19. Although aspergillosis was observed in only one case and one patient, a mixed mycotic infection demonstrating both aspergillus and mucor fungal elements was identified in one patient. Comorbidities like diabetes mellitus, indiscriminate corticosteroid use and immunosuppression leads to invasive maxillofacial fungal infections in COVID-19, which may prove to be fatal.</p>","PeriodicalId":13311,"journal":{"name":"Indian Journal of Dental Research","volume":"35 4","pages":"459-464"},"PeriodicalIF":0.0000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian Journal of Dental Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/ijdr.ijdr_691_23","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/29 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"Dentistry","Score":null,"Total":0}
引用次数: 0
Abstract
The main objective of the current systematic review was to compile and evaluate the data on opportunistic maxillofacial mycotic infections in COVID-19 patients during the treatment and post-recovery period of SARS-CoV-2 infection. Comorbidities like diabetes, corticosteroid use, and mortality among COVID-19-associated patients presenting with oral and maxillofacial fungal infections were also assessed. The review was conducted in accordance with Preferred Reporting Items for Systematic Review and Meta-analysis guidelines. A comprehensive search was carried out in the archives of Web of Science, Pubmed/Medline, Scopus, Google Scholar, Lilacs, and Livivo in combination with Boolean operators till 24th June 2022, and cross-sectional studies, case series, and case reports deliberating on maxillofacial mycoses in COVID-19 were included. The included studies were meted to the risk of bias using the Joana Briggs Institute Appraisal tools for prevalence studies, case series, and case reports. In a two-stage collection, 20 studies were included: 9 observational (3269 patients), 5 case-series (42 patients), and 6 case reports (8 patients) from 7 countries. Mucormycosis was the most commonly reported maxillofacial fungal infection (96.7%/3162 cases), followed by candidiasis (3.2%/105 cases) associated with COVID-19. Although aspergillosis was observed in only one case and one patient, a mixed mycotic infection demonstrating both aspergillus and mucor fungal elements was identified in one patient. Comorbidities like diabetes mellitus, indiscriminate corticosteroid use and immunosuppression leads to invasive maxillofacial fungal infections in COVID-19, which may prove to be fatal.
本系统综述的主要目的是收集和评估COVID-19患者在SARS-CoV-2感染治疗期间和康复后颌面部机会性真菌感染的数据。还评估了患有口腔和颌面真菌感染的covid -19相关患者的糖尿病、皮质类固醇使用和死亡率等合并症。该评价按照系统评价和荟萃分析指南的首选报告项目进行。综合检索Web of Science、Pubmed/Medline、Scopus、谷歌Scholar、Lilacs和Livivo截至2022年6月24日的档案,结合布尔运算符,纳入了关于COVID-19颌面部真菌病的横断面研究、病例系列和病例报告。纳入的研究使用乔安娜布里格斯研究所的流行病学研究、病例系列和病例报告评估工具来评估偏倚风险。在两阶段的收集中,纳入了20项研究:来自7个国家的9项观察性研究(3269例患者),5项病例系列研究(42例患者)和6项病例报告(8例患者)。颌面部真菌感染中最常见的是毛霉病(96.7%/3162例),其次是与COVID-19相关的念珠菌病(3.2%/105例)。虽然仅在一个病例和一个患者中观察到曲霉病,但在一个患者中发现了曲霉和毛霉真菌成分的混合真菌感染。糖尿病、滥用皮质类固醇和免疫抑制等合并症导致COVID-19患者侵袭性颌面部真菌感染,这可能是致命的。
期刊介绍:
Indian Journal of Dental Research (IJDR) is the official publication of the Indian Society for Dental Research (ISDR), India section of the International Association for Dental Research (IADR), published quarterly. IJDR publishes scientific papers on well designed and controlled original research involving orodental sciences. Papers may also include reports on unusual and interesting case presentations and invited review papers on significant topics.